- Oops!Something went wrong.Please try again later.
Los Angeles, California--(Newsfile Corp. - March 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between June 1, 2017 and November 9, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before March 24, 2021.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Voyager's IND submission to the FDA for VY-HTT01 failed to include key information on chemistry, manufacturing and controls ("CMC") matters including drug-device compatibility and product characterization. The Company's IND submission for VY-HTT01 was deficient based on this failure. The Company overstated the likelihood of the IND submission achieving FDA approval. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Voyager, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/78133